The aim of the study was to evaluate the association of drug resistance with β-lactamase gene types in ESBL positive E. coli and Klebsiella pneumoniae-Kp. Material and methods: A total of 251 ESBL-positive E. coli and Kp isolates obtained from urine, tracheal aspirate, wound swab and blood from patients hospitalised at the University Clinics in Skopje were detected using the ESBL set and automated Vitek 2 system. Vitek was also used for susceptibility testing (determination of MIC of 17 antimicrobial agents). Multiplex PCR was used to identify genes for different types of ESBLs in a 100 randomly selected, ESBL positive strains. Results: More of the 87 ESBL typeable isolates (61%) harbour two or more bla genes and the frequency of antibiotic resistance was high in these isolates, compared to those with a single gene. Isolates with ≥ 3 genes were highly resistant to beta-lactams and non-beta lactams used. The degree of resistance to 3 rd generation cephalosporins was also high in these isolates (MIC ≥ 64). More of the ESBL-positive isolates showed higher resistance to cefotaxime than to ceftazidime. Conclusion: Identification of the genes is necessary for the surveillance of their transmission in hospitals. Surveillance of antibiotic resistance patterns are crucial to overcome the problems associated with ESBLs.
Introduction
Beta-lactam antibiotics are the most widely used antibiotics in treating bacterial infections. The production of β-lactamases is an important mechanism of resistance to β-lactams. The most common β-lactamases are the plasmid-encoded TEM and SHV enzymes. Derivatives of these enzymes showed an enlarged ability for antibiotics destruction. Extended-spectrum beta-lactamases (ESBLs) were first described in the 1980s and they have been detected in the Klebsiella species and later in E. coli and other genera of the Enterobacteriaceae family. ESBLs have the ability to hydrolyze all cephalosporins and monobactams, but are inhibited by β-lactamase inhibitors, such as clavulanic acid [1, 2] .
ESBLs are undergoing continuous mutation, causing the development of new enzymes showing expanded substrate profiles. To date, there are over 212 derivatives of TEM betalactamases and more than 178 derivatives of SHV β-lactamases. In recent years, several new ESBLs of non-TEM, non-SHV types have emerged, such as enzymes of the CTX-M (148 variants so far), PER, VEB etc. Particularly, CTX-M type enzymes increased in E. coli and DOI: 10.2478/prilozi-2014-0004 K. pneumoniae isolates from Spain, the United Kingdom and Russia [3] [4] [5] .
ESBL are an increasingly important cause of transferable multidrug resistance in Gramnegative bacteria throughout the world. These bacteria have spread rapidly and have become a serious threat to human health worldwide. Since ESBL distribution has been shown to differ among countries, monitoring of the prevalence and the types of ESBLs may contribute to defining the breadth of the problem and appropriate therapeutic options [6] [7] [8] .
In Europe, the prevalence of these organisms varies from country to country (3% in Sweden to 34% in Portugal) [9] .
A first study on this matter has been performed in University Clinics in Skopje. Although E. coli strains were more frequently isolated than K. pneumoniae strains, the production of ESBLs was more often present in K. pneumoniae. The prevalence of ESBL-producing E. coli and K. pneumoniae had the means of 15.7% and 31%, respectively. There was a difference in the prevalence of ESBL-producing E. coli and K. pneumoniae in surgical clinics compared to that in clinics of internal medicine. ESBL-positive K. pneumoniae strains were more prevalent in surgery clinics compared to ESBL-positive E. coli strains [10, 11] . Detection and distribution of bla genes in E. coli and K. pneumoniae isolates have also been made. A difference between strains harbouring two or more genes (61%) compared to those with a single gene (39%) has been detected. The equal number of strains of E. coli and K. pneumoniae possessed a single gene, but there was a statistically significant difference in the presence of bla TEM and bla SHV between E. coli and K. pneumoniae (p = 0,007). Considering the combination of the two genes, bla TEM + bla SHV was the most common one (16%). Eight strains of E. coli and 4 strains of K. pneumoniae harbour 3 genes. Only 7 strains of K. pneumoniae (8%) and none of E. coli harbour 4 beta-lactamase genes [12] . The same E. coli and K. pneumoniae isolates were used in the present study.
The aim of the study was to evaluate the association of drug resistance with β-lactamase gene types in ESBL positive E. coli and Klebsiella pneumoniae. A confirmatory test for phenotypic detection of ESBLs (double disc assay, ESBL set, Mast Diagnostic) and Vitek 2 automated system for identification and confirmation of ESBL-production was performed on all strains with reduced susceptibility to third generation cephalosporins. Of 804 isolates, 126 (15.7%) isolates of E. coli were found to be ESBL producers and out of 403 isolates, 125 (31%) isolates of Klebsiella pneumoniae were ESBL producers. These strains were positive to at least one pair of cephalosporin/cephalosporin-clavulanic acid of the ESBL set and confirmed by Vitek. Of 251 ESBL-positive strains, 100 ESBL positive strains (E. coli-52 and K. pneumoniae-48) were randomly selected to detect the presence of genes.
Material and methods

Material
b. Control strains
For both phenotypic methods and for multiplex PCR, two ATCC strains (American Type Culture Collection, USA) have been used: K. pneumoniae ATCC 700603 as positive control and Escherichia coli ATCC 25922 as negative control.
Methods
Automated susceptibility testing using Vitek 2 compact sistem (bioMerieux, France)
MIC (minimal inhibitory concentration) of 17 antimicrobial agents: ampicillin, amoxicillin-clavulanic acid, piperacillin, piperacillin-tazobactam, cefazolin, cefoxitin, cefotaxime, ceftazidime, cefepime, imipenem, amikacin, gentamicin, ciprofloxacin, norfloxacin, tetracycline, nitrofurantoin and cotrimoxazole was determined. MIC values were interpreted as S, I and R by reference to CLSI breakpoints.
Multiplex PCR for different bla genes
Purification of whole DNA was prepared from cultured cells by the method of thermal lyses. Multiplex PCR was performed using 2 sets of primers, each targeting different regions. The first multiplex assay (named SET I) was designed to detect TEM, SHV, CTX-M IV group and OXA β-lactamase encoding genes, and the second assay (named Set II) was designed to detect the CTX-M I group, CTX-M II group and DHA encoding genes (http://www. Lahey.org/studies/webt.asp). Both PCR reactions were performed under identical conditions. All of the Set I and SET II assays produced single or multiplexed products of the predicted sizes. The methods have been described previously [12] [13] [14] [15] .
Statistical methods
Fisher exact test, Yates corrected and the difference between proportions were applied to see the significance of difference between the various genes in ESBL-producing E. coli and K. pneumoniae. Comparison of proportion was done by using the chi square test with appropriate correction for antibiotic resistance among groups. p ≤ 0.05 was considered significant.
Results
Only the positive results obtained by multiplex PCR (isolates harbouring single or more beta-lactamase genes -87) were compared to the results of Vitek 2 (MIC values to beta-lactam and non-beta lactam antibiotics). The resistant rates of different ESBL types to beta-lactam and non-beta lactam antibiotics were shown on Table 1 . All ESBL-positive isolates were resistant to ampicillin, piperacillin and cefazolin and none of them was resistant to imipenem. Among combinations of β-lactam-β-lactamase inhibitor, the activity of amoxicillin-clavulanate and piperacillin-tazobactam varied between different types of ESBL enzymes. Isolates producing 3 and more enzyme types were characterized by the highest degree of resistance to AMC compared to those with single and two genes. This difference is statistically significant. In a case of PIP/TAZ this difference is not statistically significant (p > 0.05). Although ESBLs were not active against cefoxitin, in vitro, different ESBL types showed resistance between 0-41% (isolates with CTX-M alone or associated with TEM and SHV were not resistant; strains with SHV showed the highest resistance of 41%, possibly due to overexpression of chromosomal AmpC β-lactamase). Considering cephalosporins, isolates with ≥ 3 genes were highly resistant to cefotaxime, ceftazidime and cefepime compared to the isolates with a single or two genes. This difference is statistically significant. Cefepime showed the best in vitro activity (except isolates with two enzyme types, such as TEM+SHV and TEM+CTX-M, to which cefepime was less active than ceftazidime). MICs of 64 of ceftazidime and cefotaxime were 48.3% and 79.3% of ESBL-positive isolates, respectively. Considering aminoglycosides, amikacin showed better in vitro activity than gentamycin, regardless of ESBL type (except isolates with CTX-M, which were 100% resistant to both aminoglycosides). There were no big differences in the resistance to fluoroquinolones between differrent enzyme types. Isolates with two types of beta-lactamases (OXA+CTX-M) showed the highest resistance of 88.8% The resistance to nitrofurantoin was lower compared to tetracycline and co-trimoxazole. Isolates with 3 and more ESBL types showed the highest resistance to nitrofurantoin (31.6%). There was no difference in the resistance to cotrimoxazole among various types of ESBLs (p = 0.19).
MICs of cefotaxime and ceftazidime were analysed, due to the fact that they are good ESBL substrates and due to their clinical relevance (Tables 2 and 3 ). From Table 3 it can be seen that MIC values for ceftazidime were different according to the enzyme type. In 45 isolates (52%) MIC values for ceftazidime were less than 64. In 42 of them, MIC varied between 2-32 mg/L, which according to the breakpoints can be interpreted as intermediate susceptible. For the remaining three isolates, MIC values were less than 2, and they can be interpreted as susceptible. MIC for ceftazidime ≥ 64 were detected in 42 of ESBLpositive isolates (48.3%). There was no statistically significant difference between the percentage of isolates with MIC ≥ 64 and MIC < 64 (p = 0.75).
Using a statistical method (difference between two proportions), isolates with a single gene, which were intermediate susceptible (16/42 ) and resistant (15/42), were analysed. No statistically significant difference between those two groups was detected (p = 0.82). Comparing the MIC CAZ in strains with two genes which were intermediate susceptible (26/42) to those which were resistant (8/42), a statistically significant difference was noticed (p = 0.0001). If the same statistical analysis was performed to detect the difference between the isolates with one and two genes which were intermediate susceptible (42/42) and resistant (23/42), it can be concluded that between these two groups of isolates a statistically significant difference existed (p = 0.0000). This means that a higher percentage of the isolates with one and two genes were intermediate susceptible to ceftazidime. Compared to the previous, all 19 isolates with ≥ 3 genes were highly resistant to ceftazidime with MIC ≥ 64.
More of the ESBL-positive isolates showed a higher resistance to cefotaxime than to ceftazidime. This difference is statistically significant (p = 0.001).
Discussion
The emergence of ESBL-producing organisms seems to be the result of complex interactions between the type of ESBL, the genetic background of the strain and selective pressures existing in ecologic niches. Heavy antibiotic use (especially the third generation cephalosporins) is one of the selective pressures and a risk factor for the acquisition of ESBL-producing organisms. Therefore, clinicians should be familiar with the clinical importance of these enzymes and potential strategies for dealing with them. The correct detection of ESBL-producing micro-organisms is a challenge for the laboratories, requiring not only phenotypic tests, but also genotypic tests for all genes associated with β-lactamase production [16] . Testing both ceftazidime and cefotaxime is an effective choice for ESBL screening [17] . In fact, CTX-M-type enzymes may be undetected by screening with ceftazidime alone, whereas a few TEM-type ESBL enzymes can be lost by using cefotaxime alone. Susceptibility is multifactorial, depending on ESBL substrate specificity, production of additional β-lactamases and changes of outer membrane permeability [4, 18] .
In our study ESBL-producing bacteria maintained susceptibility to imipenem. Cefoxitin is active against ESBLs in vitro, except when faced with alterations in permeability or the hyperproduction of cefaminases or AmpC β-lactamases coexisting with the ESBL, in which case the isolate proves itself resistant to this antibiotic [19] . In our study different ESBL types showed a resistant rate between 0-41%. The frequency of antibiotic resistance was high in those isolates of Klebsiella spp. which had both TEM and SHV genes, but they were statistically significant for antibiotic amoxicillin/clavulanic acid only. These isolates also had elevated MIC for cephotaxime and ceftazidime [20] . Beta-lactamase inhibitors such as clavulanate and tazobactam are comparably good inhibitors of SHV and TEM enzymes and piperacillin/tazobactam seems to have a better prospect than other inhibitor combinations against isolates with TEM derivatives enzymes [16] . In our study isolates producing 3 and more ESBL types were characterized by the highest degree of resistance to AMC compared to those with single or two genes. This difference is statistically significant. In the case of PIP/TAZ this difference is not statistically significant (p > 0.05). Isolates with ≥ 3 genes were highly resistant to cefotaxime, ceftazidime and cefepime compared to the isolates with single or two genes. This difference is statistically signifycant. MICs of 64 of ceftazidime and cefotaxime were 48.3% and 79.3% of ESBL-positive isolates, respectively. Cefepime showed the best in vitro activity (except isolates with two ESBL types, such as TEM+SHV and TEM+CTX-M, where cefepime was less active than ceftazidime). Although the hydrolytic capacity of the ESBL enzymes against this antibiotic is variable, its use is not recommendable because of failures described in the past [21] . In our study amikacin was more active than gentamicin against all ESBL-types. Some studies have indicated that amikacin is a valuable option for treatment [6] . There were no big differences in the resistance to fluoroquinolones between differrent types of ESBLs. The highest resistance of 88.8% was shown in isolates with two types of ESBLs (OXA+CTX-M). The resistance to nitrofurantoin was lower compared to tetracycline and co-trimoxazole. Isolates with 3 and more ESBL types showed the highest resistance to nitrofurantoin (31.6%). Cotrimoxazole is not really useful unless an antibiogram is made. Hadziyanis et al. found no connection between the presence of ESBLs and resistance to cotrimoxazole (22) . In our study there was no difference in the resistance to cotrimoxazole among various types of ESBLs (p = 0.19).
In short, carbapenems prove to be crucial for preventing and treating life-threatening nosocomial infections. It is therefore mandatory to maintain the clinical efficacy of carbapenems (imipenem, ertapenem, meropenem, doripenem), which have become antimicrobial drugs of last resort. In the case of non-life-threatening infections and in non-outbreak situations, it is not necessary to administer carbapenems. The heavy use of carbapenems may, in fact, favour the selection of Stenotrophomonas maltophilia (a species naturally resistant to these drugs) [4] . Carbapenem-resistant Enterobacteriaceae have been reported worldwide as a consequence largely of acquisition of carbapenemase genes. It is notable that K. pneumoniae isolates producing carbapenemases and different enterobacteria encoding metallo-β-lactamases have recently been detected in the Mediterranean area [23] [24] [25] .
Conclusion
It can be concluded that ESBL-producing E. coli and K. pneumoniae had elevated MIC for cephotaxime and ceftazidime. More of the 87 ESBL typeable isolates (61%) harbour ≥ 2 beta-lactamase genes and the frequency of antibiotic resistance was high in those isolates, compared to those with a single gene. The genotypic methods help us to confirm the genes responsible for ESBL production. The correct identification of the genes involved in ESBLmediated resistance, as well as judicious usage of extended-spectrum cephalosporins, periodic surveillance of antibiotic resistance patterns and infection control measures are crucial to overcome the problems associated with ESBLs.
